Successful treatment of a child having generalized Kaposi's sarcoma after living donor liver transplantation with conversion to sirolimus.
SRL is a new and potent immunosuppressive agent that has been successfully introduced in organ transplantation. In contrast to other immunosuppressive agents, SRL has a potent antitumor activity both in vitro and in vivo. Herein, we report a child with Kaposi's sarcoma that was diagnosed 30 months after LDLT and treated successfully with only conversion to SRL monotherapy. KS regressed completely at the end of the first month and remained in remission during 28 months follow-up.
Yuksekkaya
Hasan A
HA
Pediatric Gastroenterology, Hepatology, and Nutrition, Ege University School of Medicine, Bornova, Izmir, Turkey.
Arikan
Cigdem
C
Yazici
Ayse
A
Baran
Masallah
M
Aydogdu
Sema
S
Kilic
Murat
M
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus